Caption Management’s PDS Biotechnology PDSB Stock Holding History

Caption Management’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8,181	Closed	-$40.7K	–	1572
2023 Q4	$40.7K	Buy	+8,181	New	+$40.7K	﹤0.01%	1227

Other funds holding PDSB

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Caption Management's PDSB Position: Q1 2024 in Review

Caption Management sold out of PDS Biotechnology (PDSB) in Q1 2024, closing a stake of 8,181 shares — an estimated $40.7K sold.

Caption Management first reported a position in PDSB in Q4 2023 and held it in 1 quarter. The position peaked at $40.7K in Q4 2023. 72 funds tracked by Wall St. Rank hold PDSB as of Q1 2024.

Caption Management reported no remaining PDS Biotechnology position as of Q1 2024 after selling out during the quarter.
Caption Management sold 8,181 PDS Biotechnology shares in Q1 2024, an estimated $40.7K.
Caption Management first reported a position in PDS Biotechnology in Q4 2023 and held it in 1 quarter.
Caption Management's PDS Biotechnology position peaked at $40.7K in Q4 2023.
72 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2024.

Based on Caption Management's 13F filing for Q1 2024, filed 15 May 2024.